Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Viridian Therapeutics Secures Commercial Manufacturing Agreement with WuXi Biologics for Veligrotug – Anti-IGF-1R Antibody Advances Toward Thyroid Eye Disease Treatment

Fineline Cube May 28, 2026
Company Deals

Shanghai Pharma and Trinomab Partner to Commercialize Xintituo in Philippines – World’s First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Expands Overseas

Fineline Cube May 28, 2026
Company Deals Drug

Shanghai Pharma Partners with BeOne Medicines on Imdelltra Distribution – Expanding Access to DLL3/CD3 Bispecific T-Cell Engager in China

Fineline Cube May 28, 2026
Company Deals Drug

TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC

Fineline Cube May 27, 2026
Company Deals

Fosun Pharma Invests RMB 220 Million in Hepa Thera, Becomes Second Largest Shareholder in Liver Disease Biotech

Fineline Cube May 27, 2026
Policy / Regulatory

NMPA Issues Comprehensive Guidelines for Online Prescription Drug Retail, Mandating Human Pharmacist Review and AI Prescription Blocking

Fineline Cube May 26, 2026
Company Drug

AbbVie Secures FDA Approval for DECNUPAZ in Blastic Plasmacytoid Dendritic Cell Neoplasm – First CD123-Targeting ADC Addresses Ultra-Rare Hematologic Malignancy

Fineline Cube May 28, 2026
Company Drug

InnoCare Pharma Secures Australian TGA Approval for Hibruka in Relapsed/Refractory Mantle Cell Lymphoma – Highly Selective BTK Inhibitor Expands International Footprint

Fineline Cube May 28, 2026
Company Deals

KingWise Partners with Truking Technology for Gynecological Tumor Gene Therapy Facilities

Fineline Cube Nov 27, 2023

KingWise, a Wuhan-based specialist in gynecological tumor diagnostics, has entered into a partnership with local...

Company Drug

Takeda’s Takecab Receives NMPA Approval for Helicobacter pylori Eradication in China

Fineline Cube Nov 27, 2023

Takeda (TYO: 4502), a Japan-based pharmaceutical company, has announced that it has received another indication...

Company Drug

Fujian Cosunter’s Oral COVID-19 Therapy Receives Conditional Approval in China

Fineline Cube Nov 27, 2023

Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436), a Chinese pharmaceutical company, has announced that its...

Company Drug

Sichuan Kelun Pharmaceutical’s RET Inhibitor A400 Earns FDA Orphan Drug Designation

Fineline Cube Nov 27, 2023

Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), a Chinese pharmaceutical company, through its innovative drug...

Company Medical Device

Yantai Dongcheng Pharmaceutical Gets Green Light for Prostate Cancer Diagnostic Drug Trial

Fineline Cube Nov 27, 2023

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has announced that...

Company Deals

OrbusNeich Medical Group to Acquire Majority Stake in Indonesian Distributor PT Revass Utama Medika

Fineline Cube Nov 27, 2023

OrbusNeich Medical Group Ltd (HKG: 6929), a Wholly Owned Foreign Enterprise (WOFE) specializing in vascular...

Company Drug

Kintor Pharmaceutical’s KX-826 Shows Promising Results in Phase III AGA Clinical Trial

Fineline Cube Nov 27, 2023

Kintor Pharmaceutical Ltd (HKG: 9939), a China-based pharmaceutical company, has released topline data from a...

Company Drug

EirGenix’s Trastuzumab Biosimilar Receives European Commission Marketing Approval

Fineline Cube Nov 27, 2023

EirGenix Inc., (6589.TT) a Taiwan-based pharmaceutical company, has announced that it has received marketing approval...

Company Deals

Broncus Medical and Hangzhou Norchant Terminate Licensing Agreement with Cancellation Fee

Fineline Cube Nov 27, 2023

Broncus Medical Inc., (HKG: 2216) a provider of lung disease precision intervention solutions with operations...

Company

FDA Raises Concerns Over Research Conditions at Roche’s Genentech Trial Site

Fineline Cube Nov 27, 2023

The US Food and Drug Administration (FDA) has voiced concerns regarding the research conditions at...

Company Drug

Jiangxi Jemincare Group Secures NMPA Approval for Generic Ibrance Capsules

Fineline Cube Nov 27, 2023

Jiangxi Jemincare Group, a Chinese pharmaceutical company, has announced that it has received market approval...

Policy / Regulatory R&D

China’s CDE Releases Draft Guidelines for Decentralized Trials in Rare Disease Drug Development

Fineline Cube Nov 27, 2023

China’s Center for Drug Evaluation (CDE) has released draft “Technical Guidelines for the Application of...

Company Legal / IP

AbbVie Sues to Protect Rinvoq from Generic Competition in the US Market

Fineline Cube Nov 27, 2023

AbbVie (NYSE: ABBV) has initiated legal action in the US to safeguard its blockbuster drug...

Company Drug

Novo Nordisk Sets February 2024 Launch for Wegovy in Japan, Expanding into Asia

Fineline Cube Nov 27, 2023

Novo Nordisk (CPH: NOVO-B), headquartered in Denmark, has announced that it will launch its anti-obesity...

Company Drug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for Phase Ib/II Study of Dalpiciclib and HRS-8080

Fineline Cube Nov 24, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it received approval from...

Company Drug

Fosun Pharmaceutical Gets FDA Green Light for HLX42 ADC Clinical Study

Fineline Cube Nov 24, 2023

Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) has received approval from the US...

Company Deals

Simcere Pharmaceutical Secures Rights to Develop Rademikibart in China

Fineline Cube Nov 24, 2023

China’s Simcere Pharmaceutical Co., Ltd (HKG: 2096) has entered into an agreement to acquire the...

Company

Bayer Invests USD 130 Million in Parenteral Drugs Manufacturing Site in Germany

Fineline Cube Nov 24, 2023

Bayer (ETR: BAYN) has inaugurated a new state-of-the-art parenteral drugs manufacturing site at its German...

Company

Novo Nordisk Invests DKK 16 Billion to Expand French Production Facility

Fineline Cube Nov 24, 2023

Denmark-based pharmaceutical giant Novo Nordisk (CPH: NOVO-B) has initiated an expansion of its production facility...

Company Deals

Shanghai Escugen Partners with Foreseen Biotechnology for ADC Development

Fineline Cube Nov 24, 2023

China-based Shanghai Escugen has entered into a partnership with domestic firm Foreseen Biotechnology to develop...

Posts pagination

1 … 445 446 447 … 673

Recent updates

  • AbbVie Secures FDA Approval for DECNUPAZ in Blastic Plasmacytoid Dendritic Cell Neoplasm – First CD123-Targeting ADC Addresses Ultra-Rare Hematologic Malignancy
  • InnoCare Pharma Secures Australian TGA Approval for Hibruka in Relapsed/Refractory Mantle Cell Lymphoma – Highly Selective BTK Inhibitor Expands International Footprint
  • Shanghai Yizhong Pharma’s Trifunctional Antibody Fusion Protein YXC-001 Receives IND Acceptance in China – Novel Approach Targets Advanced Solid Tumors with Precision IL-2 Delivery
  • Viridian Therapeutics Secures Commercial Manufacturing Agreement with WuXi Biologics for Veligrotug – Anti-IGF-1R Antibody Advances Toward Thyroid Eye Disease Treatment
  • Shanghai Pharma and Trinomab Partner to Commercialize Xintituo in Philippines – World’s First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Expands Overseas
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AbbVie Secures FDA Approval for DECNUPAZ in Blastic Plasmacytoid Dendritic Cell Neoplasm – First CD123-Targeting ADC Addresses Ultra-Rare Hematologic Malignancy

Company Drug

InnoCare Pharma Secures Australian TGA Approval for Hibruka in Relapsed/Refractory Mantle Cell Lymphoma – Highly Selective BTK Inhibitor Expands International Footprint

Company Drug

Shanghai Yizhong Pharma’s Trifunctional Antibody Fusion Protein YXC-001 Receives IND Acceptance in China – Novel Approach Targets Advanced Solid Tumors with Precision IL-2 Delivery

Company Deals

Viridian Therapeutics Secures Commercial Manufacturing Agreement with WuXi Biologics for Veligrotug – Anti-IGF-1R Antibody Advances Toward Thyroid Eye Disease Treatment

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.